UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Stock Information for CloudMD Software & Services Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CloudMD Software & Services Inc

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Relmada Issues Mid-Year CEO Letter to Shareholders
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.